New cancer therapies. Are haematopoietic cell transplants a dead duck?
- 28 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (5), 1086-1089
- https://doi.org/10.1038/s41409-020-01151-3
Abstract
Recent therapy advances for haematological cancers including new drugs and targeted and immune therapies raise the question whether there is a future for haematopoietic cell transplants. Although encouraging, the survival improvements achieved with these new modalities in persons who might otherwise receive a transplant are modest. Furthermore, these modalities are likely to be complementary, not competitive. For example, randomised trials in multiple myeloma, the most common transplants, indicate an ongoing role for transplant despite new anti-myeloma drugs. Targeted therapies in myeloid cancers are estimated to be effective in only about 10 percent of persons with these cancers. The potential impact of current immune therapies on transplant activity is also limited because: (1) they predominately target B-cell rather than myeloid cancers; (2) many successful immune therapy recipients subsequently receive a transplant; (3) considerable data indicate much of the efficacy of allotransplants results from allogeneic rather than cancer-specific immunity not expected to operate with current immune therapies; and (4) they are at an early development stage with unknown long-term safety and efficacy. These data suggest an ongoing role for haematopoietic cell transplants in diverse haematological and genetic disorders.Keywords
This publication has 23 references indexed in Scilit:
- Precision medicine in acute myeloid leukemia: Hope, hype or both?Leukemia Research, 2016
- Is there really a specific graft-versus-leukaemia effect?Bone Marrow Transplantation, 2016
- One million haemopoietic stem-cell transplants: a retrospective observational studyThe Lancet Haematology, 2015
- G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agentCytokine & Growth Factor Reviews, 2014
- Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?Leukemia, 2014
- Recombinant cytokines and hematopoietic growth factors in allogeneic and autologous bone marrow transplantationCancer treatment and research, 1997
- History of bone marrow transplantationClinics in Haematology, 1983
- Bone-Marrow TransplantationThe New England Journal of Medicine, 1975
- Bone-Marrow TransplantationThe New England Journal of Medicine, 1975
- Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and ChemotherapyThe New England Journal of Medicine, 1957